Market Overview:
The global natural killer cells therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer and other diseases, rising demand for targeted therapies, and technological advancements in the field of NK cell therapy. The global natural killer cells therapeutics market can be segmented on the basis of type, application, and region. On the basis of type, the market can be divided into NK cell therapies and NK cell directed antibodies. The NK cell therapies segment is expected to grow at a higher CAGR than that of the NK cell directed antibodies segment during the forecast period from 2018 to 2030. This growth can be attributed to increasing demand for novel treatments for cancer and other diseases, growing awareness about benefits offered by NK cells therapies over traditional treatments such as chemotherapy or radiation therapy, and technological advancements in this field. On the basis of application,the global natural killer cells therapeutics market can be divided into cancer treatment, gastrointestinal diseases treatment (including Crohn’s diseaseand ulcerative colitis), immunoproliferative disorders treatment (including lymphomaand leukemia), and others (such as multiple sclerosis).
Product Definition:
Natural Killer Cells Therapeutics is the use of natural killer cells to treat diseases. Natural killer cells are a type of lymphocyte that attacks tumor cells and virus-infected cells. They are an important part of the immune system, and their therapeutic use may be helpful in treating cancer, viral infections, and autoimmune diseases.
NK Cell Therapies:
Natural killer (NK) cells are a type of white blood cell that constitutes about 1% to 3% of the total blood volume. They are also known as perforative cells because they possess the ability to destroy infected cells and cancerous tumors.
NK Cell Directed Antibodies:
NK cell directed antibodies are used by Natural killer (NK) cells to identify and target cancer cells. These antibodies can also be used in the treatment of various cancers. The use of these products has increased significantly due to their ability to act as a therapy for patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Application Insights:
The cancer segment dominated the global market in 2017. This can be attributed to the rising prevalence of various types of cancers, increasing research and development activities pertaining to NK cell therapies for cancer treatment, and growing awareness about these cells among oncology professionals. For instance, a study published in March 2018 by NCBI states that out of all available oncology drugs, natural killer cells-based therapy is most effective against lung cancer.
NK cell therapies are being studied for their potential use as an alternative or addition therapy for treating patients with advanced solid tumors such as non-small cell lung carcinoma and gastrointestinal stromal tumor (GIST). In addition, they are also being considered as a potential therapeutic modality in the treatment of other malignant diseases including multiple myeloma and melanoma due to their ability to recognize & kill tumor cells without harming normal tissues.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities by companies and their efforts to commercialize novel therapeutics as quickly as possible, and high healthcare expenditure in this region. Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing incidence of cancer and other immunoproliferative disorders coupled with growing awareness about available treatment options. Moreover, rising disposable income levels are anticipated to boost demand for oncology drugs over the forecast period.
In 2016, a study was published regarding NK cell therapy efficacy in patients with advanced solid tumors who have not received prior treatment or after failure of first line therapy from China (Jiang et al., 2016).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the natural killer cells therapeutics market. According to a study by the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012, and this number is expected to increase to 21 million by 2030. This growing prevalence of cancer is expected to drive demand for natural killer cells therapeutics products over the forecast period.
- Rising awareness about benefits of NK cell therapy: There is a rising awareness among patients and healthcare professionals about the benefits of NK cell therapy in treating various types of cancers. This growing awareness is likely to boost demand for natural killer cells therapeutics products over the forecast period.
- Technological advancements in NK cell therapies: The technological advancements in NK cell therapies are another major growth driver for this market. These advancements have led to development and commercialization of novel therapeutic approaches such as adoptive transfer therapy, which involves infusion or injectionof autologous or allogeneic activated NK cells into patients suffering from various typesof cancers including hematologic malignancies, solid tumors, and metastatic disease sites..This trendisexpectedtoresultinhigherdemandfornaturalkillercellstherapeuticproductsinthefuture..
Scope Of The Report
Report Attributes
Report Details
Report Title
Natural Killer Cells Therapeutics Market Research Report
By Type
NK Cell Therapies, NK Cell Directed Antibodies
By Application
Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others
By Companies
Affimed, Celgene, Fate Therapeutics, Fortress Biotech, Glycostem Therapeutics, Innate Pharma, Nantkwest, Nkarta Therapeutics, NKT Therapeutics, Ziopharm Oncology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
173
Number of Tables & Figures
122
Customization Available
Yes, the report can be customized as per your need.
Global Natural Killer Cells Therapeutics Market Report Segments:
The global Natural Killer Cells Therapeutics market is segmented on the basis of:
Types
NK Cell Therapies, NK Cell Directed Antibodies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Affimed
- Celgene
- Fate Therapeutics
- Fortress Biotech
- Glycostem Therapeutics
- Innate Pharma
- Nantkwest
- Nkarta Therapeutics
- NKT Therapeutics
- Ziopharm Oncology
Highlights of The Natural Killer Cells Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- NK Cell Therapies
- NK Cell Directed Antibodies
- By Application:
- Cancer
- Gastrointestinal Diseases
- Immunoproliferative Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Natural Killer Cells Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Natural Killer Cells Therapeutics is a biotechnology company that specializes in the development of novel therapeutics for cancer and other diseases. The company's products are derived from natural killer cells, which are immune cells that play an important role in defending the body against infection and disease. Natural Killer Cells Therapeutics' products include drugs targeting various types of cancer, as well as vaccines and other therapies to treat autoimmune diseases such as Crohn's disease and multiple sclerosis.
Some of the major players in the natural killer cells therapeutics market are Affimed, Celgene, Fate Therapeutics, Fortress Biotech, Glycostem Therapeutics, Innate Pharma, Nantkwest, Nkarta Therapeutics, NKT Therapeutics, Ziopharm Oncology.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Natural Killer Cells Therapeutics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Natural Killer Cells Therapeutics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Natural Killer Cells Therapeutics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Natural Killer Cells Therapeutics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Natural Killer Cells Therapeutics Market Size & Forecast, 2018-2028 4.5.1 Natural Killer Cells Therapeutics Market Size and Y-o-Y Growth 4.5.2 Natural Killer Cells Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Natural Killer Cells Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Natural Killer Cells Therapeutics Market Size Forecast by Type
5.2.1 NK Cell Therapies
5.2.2 NK Cell Directed Antibodies
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Natural Killer Cells Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Natural Killer Cells Therapeutics Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Gastrointestinal Diseases
6.2.3 Immunoproliferative Disorders
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Natural Killer Cells Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Natural Killer Cells Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Natural Killer Cells Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Natural Killer Cells Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Natural Killer Cells Therapeutics Market Size Forecast by Type
9.6.1 NK Cell Therapies
9.6.2 NK Cell Directed Antibodies
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Natural Killer Cells Therapeutics Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Gastrointestinal Diseases
9.10.3 Immunoproliferative Disorders
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Natural Killer Cells Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Natural Killer Cells Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Natural Killer Cells Therapeutics Market Size Forecast by Type
10.6.1 NK Cell Therapies
10.6.2 NK Cell Directed Antibodies
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Natural Killer Cells Therapeutics Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Gastrointestinal Diseases
10.10.3 Immunoproliferative Disorders
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Natural Killer Cells Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Natural Killer Cells Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Natural Killer Cells Therapeutics Market Size Forecast by Type
11.6.1 NK Cell Therapies
11.6.2 NK Cell Directed Antibodies
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Natural Killer Cells Therapeutics Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Gastrointestinal Diseases
11.10.3 Immunoproliferative Disorders
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Natural Killer Cells Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Natural Killer Cells Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Natural Killer Cells Therapeutics Market Size Forecast by Type
12.6.1 NK Cell Therapies
12.6.2 NK Cell Directed Antibodies
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Natural Killer Cells Therapeutics Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Gastrointestinal Diseases
12.10.3 Immunoproliferative Disorders
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Natural Killer Cells Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Natural Killer Cells Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Natural Killer Cells Therapeutics Market Size Forecast by Type
13.6.1 NK Cell Therapies
13.6.2 NK Cell Directed Antibodies
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Natural Killer Cells Therapeutics Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Gastrointestinal Diseases
13.10.3 Immunoproliferative Disorders
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Natural Killer Cells Therapeutics Market: Competitive Dashboard
14.2 Global Natural Killer Cells Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Affimed
14.3.2 Celgene
14.3.3 Fate Therapeutics
14.3.4 Fortress Biotech
14.3.5 Glycostem Therapeutics
14.3.6 Innate Pharma
14.3.7 Nantkwest
14.3.8 Nkarta Therapeutics
14.3.9 NKT Therapeutics
14.3.10 Ziopharm Oncology